Treatment of Methicillin-Sensitive Staphylococcus epidermidis (MSSE) Bacteremia
For MSSE bacteremia, treat with cefazolin 2 g IV every 8 hours or an antistaphylococcal penicillin (nafcillin/oxacillin 2 g IV every 6 hours) for 2-6 weeks depending on complexity, with mandatory source control and repeat blood cultures to document clearance.
Antibiotic Selection
The treatment approach for MSSE bacteremia directly parallels methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia, as coagulase-negative staphylococci like S. epidermidis share similar susceptibility patterns when methicillin-sensitive 1.
First-Line Options:
- Cefazolin: 2 g IV every 8 hours (preferred for safety profile and recent evidence) 2, 3
- Antistaphylococcal penicillins: Nafcillin or oxacillin 2 g IV every 6 hours 4, 5
Cefazolin is increasingly preferred based on the 2024 SNAP trial demonstrating noninferiority to antistaphylococcal penicillins for MSSA bacteremia (90-day mortality 15.0% vs 17.0%, adjusted OR 0.81) with significantly lower rates of acute kidney injury (13.9% vs 19.6%) 2. This evidence directly applies to MSSE given identical mechanisms of methicillin susceptibility.
For β-Lactam Allergic Patients:
- Vancomycin: 15 mg/kg IV every 12 hours (target trough 15-20 mcg/mL for serious infections) 6
- Consider desensitization protocols for true penicillin allergy if history is questionable 5
- For simple rash history (non-anaphylactoid), cefazolin remains reasonable 5
Duration of Therapy
Treatment duration depends on complexity and presence of complications:
Uncomplicated Bacteremia (2 weeks minimum):
- Negative follow-up blood cultures at 2-4 days
- No endocarditis on echocardiography
- No implanted prostheses
- Defervescence within 72 hours
- No metastatic infection sites 6
Complicated Bacteremia (4-6 weeks):
- Persistent bacteremia beyond 48-72 hours
- Presence of endocarditis
- Implanted devices (especially if not removed)
- Metastatic infection foci
- Delayed source control 6, 3
Critical Management Components
Source Control (Mandatory):
Remove all infected intravascular catheters and foreign devices immediately 1, 3. S. epidermidis infections are characteristically device-associated, and antimicrobial therapy alone without device removal has high failure rates 1. For prosthetic valve endocarditis, surgical consultation is essential 5.
Follow-Up Blood Cultures:
Obtain repeat blood cultures 2-4 days after initial positive cultures to document clearance 6, 3. Persistent bacteremia ≥48 hours increases 90-day mortality to 39% and mandates extended therapy and aggressive source control 3.
Echocardiography:
- Transthoracic echocardiography (TTE) for all patients with bacteremia 6
- Transesophageal echocardiography (TEE) if:
Additional Imaging:
Pursue CT or MRI based on clinical symptoms to identify metastatic foci (vertebral osteomyelitis, epidural abscess, septic arthritis, visceral abscesses) 3.
What NOT to Do
Do not add gentamicin or rifampin to β-lactam therapy for uncomplicated bacteremia—combination therapy increases nephrotoxicity without mortality benefit 6, 5. Gentamicin is specifically not recommended for staphylococcal bacteremia 5.
Do not use vancomycin for MSSE if β-lactams are tolerated—vancomycin has inferior outcomes for methicillin-susceptible staphylococcal infections 7, 3.
Special Considerations for S. epidermidis
Unlike S. aureus, S. epidermidis bacteremia is typically:
- Hospital-acquired and device-associated
- Lower virulence but more occult presentation
- Frequently methicillin-resistant in nosocomial settings (verify susceptibilities carefully) 1
For methicillin-resistant S. epidermidis, vancomycin becomes first-line, often combined with rifampin for serious infections involving prosthetic devices 1.
Common Pitfalls
- Assuming contamination: S. epidermidis is often dismissed as a contaminant, but multiple positive cultures with clinical signs mandate treatment 1
- Inadequate source control: Leaving infected devices in place guarantees treatment failure
- Premature discontinuation: Ensure documented clearance with repeat cultures before shortening therapy
- Missing metastatic foci: Maintain high suspicion for seeding of bones, joints, and implanted hardware